quinazolines has been researched along with lipofectamine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Booth, L; Chen, CS; Cruickshanks, N; Dent, P; Grant, S; Ridder, T | 1 |
1 other study(ies) available for quinazolines and lipofectamine
| Article | Year |
|---|---|
OSU-03012 interacts with lapatinib to kill brain cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; Beclin-1; Benzoquinones; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Genes, erbB-1; Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Lipids; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrazoles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; RNA Interference; RNA, Small Interfering; Signal Transduction; Sulfonamides | 2012 |